Equities

VIDEO: Paradigm Biopharma (ASX:PAR) pursuing FDA review

Video thumbnail
Video Player is loading.
Current Time 0:09
Duration 8:02
Loaded: 9.95%
Stream Type LIVE
Remaining Time 7:53
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • default, selected

    Paradigm Biopharma is continuing to progress the regulatory review of its novel treatment for conditions including osteoarthritis and Mucopolysaccharidosis.

    The company is developing an injectable iPPS treatment for diseases where inflammation plays a major pathogenic role.

    The late stage drug development company is working towards a Phase 3 clinical trial of its iPPS treatment.

    Disclaimer
    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.
    Publisher
    Paradigm Biopharmaceuticals